GH Secretagogues Class Overview Monograph

What Is the GH Secretagogues Drug Class?

Growth hormone secretagogues are agents that stimulate the pituitary somatotroph cells to release GH through receptor-mediated pathways rather than supplying GH exogenously. The class spans structurally diverse molecules, from six-amino-acid peptides such as ipamorelin to orally bioavailable small molecules such as MK-677 (ibutamoren). All share one functional outcome: a transient, physiologically shaped rise in circulating GH and, downstream, IGF-1.

How GHS Differ from Recombinant GH

Exogenous recombinant human GH (rhGH) such as somatropin delivers a sustained, supraphysiologic GH signal that suppresses endogenous secretion via somatostatin feedback. GHS agents, by contrast, work upstream of the pituitary to amplify the body's own secretory pulses. Because the hypothalamic-pituitary feedback axis remains intact, somatostatin counter-regulation limits IGF-1 accumulation and reduces the risk of the dose-dependent adverse effects seen with somatropin, including acromegalic features and significant insulin resistance [1].

A 2019 review in Endocrine Reviews noted that "pulsatile GH delivery, as achieved by secretagogue-based approaches, more closely replicates physiological GH dynamics compared with continuous or daily bolus exogenous administration" [2].

Historical Development

The first synthetic GHS, GHRP-6, was identified by Bowers and colleagues in the 1980s [3]. Sermorelin, a 29-amino-acid GHRH analog, received FDA approval in 1997 for pediatric GH deficiency before being voluntarily withdrawn from the U.S. Market by the manufacturer in 2008 for commercial, not safety, reasons. Tesamorelin gained FDA approval in 2010 for HIV-associated lipodystrophy based on phase 3 trial data [4]. MK-677 has remained an investigational compound despite decades of clinical study.

Receptor Pharmacology and Mechanism of Action

Two distinct receptor pathways account for GH release within this class. Understanding both is necessary for rational agent selection.

GHRH Receptor (GHRHR) Pathway

Sermorelin, tesamorelin, and CJC-1295 are structural analogs of the 44-amino-acid endogenous GHRH peptide. They bind the GHRHR on pituitary somatotrophs, activate adenylyl cyclase via Gs protein coupling, raise intracellular cAMP, and trigger GH exocytosis [5]. Tesamorelin carries a trans-3-hexenoic acid modification at the N-terminus that increases plasma half-life from roughly 7 minutes (native GHRH) to approximately 26 minutes, meaningfully improving pharmacodynamic duration [4].

CJC-1295 DAC (with drug affinity complex) extends half-life further to approximately 6 to 8 days by covalent albumin binding via the maleimide-lysine moiety, producing a sustained GHRH signal rather than a discrete pulse. This extended activity may reduce secretory pulsatility and is one reason many clinicians prefer shorter-acting GHRHR analogs for physiological mimicry [6].

GHS-R1a (Ghrelin Receptor) Pathway

Ipamorelin, GHRP-2, GHRP-6, and MK-677 bind GHS-R1a, the receptor for the endogenous hunger hormone ghrelin. GHS-R1a activation stimulates GH release through a phospholipase C / IP3 / intracellular calcium pathway, independent of GHRHR signaling [7]. The two pathways are synergistic: co-administration of a GHRHR analog with a GHS-R1a agonist produces GH release approximately 2- to 3-fold greater than either agent alone, a combination strategy used in both research and clinical practice [8].

Selectivity Differences Among GHS-R1a Agonists

Not all ghrelin-receptor agonists within this class are pharmacologically equivalent at the receptor level. GHRP-6 stimulates appetite and significantly raises cortisol and prolactin at therapeutic doses. GHRP-2 is more potent at GHS-R1a but retains a cortisol signal. Ipamorelin is the most receptor-selective GHRP currently in clinical use: at doses up to 90 mcg/kg IV, it produced no statistically significant change in cortisol, prolactin, FSH, LH, or TSH in a controlled crossover study (N=8) published in Growth Hormone and IGF Research [9]. This selectivity profile explains why ipamorelin has become the preferred GHRP in clinical telehealth practice.

Individual Agents: Pharmacokinetics and Clinical Profiles

Ipamorelin

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) administered subcutaneously. Peak GH release occurs 30 to 60 minutes post-injection. Plasma half-life is approximately 2 hours. At 200 mcg SC in healthy adults, mean GH Cmax values of 10 to 20 ng/mL have been reported, compared with a baseline of roughly 0.5 to 1.0 ng/mL [9]. Ipamorelin is compounded in the United States and is not FDA-approved as a finished drug product; prescribers must use 503A or 503B compounding pharmacies.

Sermorelin

Sermorelin acetate is the 29-amino-acid N-terminal fragment of GHRH. It was FDA-approved as Geref (Serono) for stimulation testing and for treatment of idiopathic GH deficiency in children. Half-life is 10 to 20 minutes after SC injection. A 12-month open-label study in 30 adults with partial GH deficiency (mean age 51 years) found that nightly SC sermorelin 0.2 to 0.3 mg increased IGF-1 by a mean of 38% from baseline without significant changes in fasting glucose [10].

Tesamorelin (Egrifta SV)

Tesamorelin is the only FDA-approved GHS for an approved indication. In the key phase 3 LIPO-010 trial (N=816 HIV-positive adults with abdominal lipodystrophy), tesamorelin 2 mg SC daily for 26 weeks reduced visceral adipose tissue (VAT) by 15.2% versus 1.4% placebo (P<0.001) and increased IGF-1 by 181 mcg/L versus 20 mcg/L placebo [4]. The FDA label carries a warning regarding glucose intolerance: HbA1c rose by a mean of 0.12% in the treated group. Prescribers should check HbA1c at baseline and at 3 months [11].

MK-677 (Ibutamoren)

MK-677 is an orally active, non-peptide GHS-R1a agonist with a half-life of approximately 4 to 6 hours and a prolonged pharmacodynamic effect lasting up to 24 hours after a single 25 mg dose [12]. In a 24-month randomized controlled trial in 65 hip-fracture patients (mean age 79 years), MK-677 25 mg daily significantly increased serum IGF-1 by 84% and lean body mass by 1.67 kg versus placebo (P<0.001), though it did not reduce fall incidence [13]. MK-677 is not FDA-approved and is currently classified as an investigational new drug; U.S. Prescribers cannot legally dispense it as a pharmaceutical compound.

CJC-1295 (Without DAC)

CJC-1295 without DAC (also called Mod GRF 1-29) is a 29-amino-acid GHRH analog with four amino-acid substitutions that extend plasma half-life to approximately 30 minutes. It is typically co-administered with ipamorelin in a single injection. The combination strategy is supported mechanistically by the combination data referenced above [8], though published RCTs with this specific binary combination in non-HIV, non-deficient adult populations remain sparse.

Clinical Applications and Evidence Base

Body Composition and Muscle Preservation

Reduced GH secretion with aging ("somatopause") is associated with decreased lean mass, increased visceral fat, and impaired physical function [14]. GHS agents address this by amplifying residual somatotroph function. A randomized, double-blind, placebo-controlled trial by Svensson et al. (N=24 healthy men aged 22 to 33 years) found that ipamorelin 200 mcg SC three times daily for 7 days raised 24-hour mean GH concentration by 51% versus placebo, with no significant effect on cortisol [9].

In older populations, the MK-677 hip-fracture data (N=65) demonstrated a 1.67 kg lean mass gain over 24 months [13]. These gains are modest compared with anabolic-androgenic therapy but occur without suppression of the hypothalamic-pituitary-gonadal axis, making GHS a useful adjunct to TRT rather than a replacement.

HIV-Associated Lipodystrophy

Tesamorelin carries the highest level of clinical evidence within the class. Beyond the LIPO-010 trial [4], a 52-week extension study (N=403) confirmed sustained VAT reductions of 17.8% and showed that VAT rebounded within 12 weeks of discontinuation, confirming therapy must be maintained to preserve effect [11]. The FDA label specifies 2 mg SC once daily into the abdomen.

Recovery and Sleep Quality

GH secretion is highest during slow-wave sleep stage N3. Bedtime administration of ipamorelin or sermorelin is designed to amplify the natural nocturnal GH pulse. While large RCT data on sleep architecture are limited, a placebo-controlled crossover study (N=10 older adults) found that GHRH intranasal administration increased N3 sleep duration by a mean of 20 minutes versus placebo (P<0.05) [15]. Prescribers commonly recommend SC injection 30 to 60 minutes before sleep to time the GH pulse with the first deep-sleep cycle.

GH Stimulation Testing

Sermorelin 1 mcg/kg IV (the Geref diagnostic dose) has been used as a stimulation test for GH reserve. A peak GH response below 7 ng/mL at 45 to 60 minutes post-injection is consistent with GH deficiency per the Endocrine Society 2011 guidelines on adult GH deficiency [16]. This application requires intact pituitary function; hypothalamic disease does not preclude a positive sermorelin response.

Dosing and Administration

The table below represents a prescriber-level dosing reference for commonly used GHS agents. Doses reflect ranges reported in the peer-reviewed literature and clinical practice; only tesamorelin has an FDA-approved prescribing label.

| Agent | Route | Typical Dose | Frequency | Notes | |---|---|---|---|---| | Ipamorelin | SC | 200 to 300 mcg | Once nightly at bedtime | Cycle 3 months on, 1 month off per standard practice | | Sermorelin | SC | 0.2 to 0.3 mg | Once nightly at bedtime | Refrigerate; use within 30 days of reconstitution | | Tesamorelin (Egrifta SV) | SC (abdomen) | 2 mg | Once daily | Only FDA-approved GHS; see full prescribing info [11] | | CJC-1295 (no DAC) | SC | 100 to 200 mcg | Once nightly, with ipamorelin | Combine in same syringe; inject immediately | | MK-677 | Oral | 10 to 25 mg | Once daily (morning or evening) | Investigational; not legally dispensable as Rx in U.S. | | GHRP-2 | SC | 100 to 200 mcg | 2 to 3x daily | Higher cortisol elevation than ipamorelin; less preferred |

Cycling: Continuous GHS administration may downregulate GHS-R1a over time [7]. A 3-months-on, 1-month-off cycle is common in clinical practice, though controlled data on optimal cycling intervals are absent from the published literature.

Injection technique: Rotate SC sites (abdomen, thigh, deltoid). Inject 30 to 60 minutes before sleep for bedtime protocols. Avoid food for 2 hours before and 30 minutes after injection, as elevated insulin from a meal blunts pituitary GH response.

Safety, Adverse Effects, and Contraindications

Common Adverse Effects

Fluid retention is the most frequently reported side effect across the class, occurring in 5 to 26% of patients in tesamorelin trials [4]. It manifests as peripheral edema, joint stiffness (arthralgia), and carpal tunnel syndrome-like paresthesias. These effects are dose-dependent and typically resolve within 2 to 4 weeks of dose reduction or discontinuation.

Insulin resistance is a class effect. GH directly antagonizes insulin signaling in adipose and skeletal muscle by reducing GLUT-4 translocation [17]. In the tesamorelin phase 3 program, the incidence of new-onset diabetes was 3.3% in the treated group versus 1.0% in placebo over 52 weeks [11]. Prescribers should obtain a fasting glucose and HbA1c at baseline, at 3 months, and every 6 months thereafter.

Injection-site reactions (erythema, pruritus, induration) occur in roughly 8 to 10% of patients using SC peptide formulations [4]. Rotating sites and allowing reconstituted peptide to reach room temperature before injection reduces local irritation.

Serious Risks and Contraindications

Active malignancy is an absolute contraindication. IGF-1 has mitogenic properties and GHS-driven IGF-1 elevation may promote tumor growth, particularly in IGF-1-receptor-positive cancers [18]. The Endocrine Society guideline on adult GH deficiency states: "GH replacement is contraindicated in patients with active malignancy, and a 12-month cancer-free interval is generally required before initiation" [16]. This guidance, though written for rhGH, applies to GHS by extension given the shared downstream IGF-1 signal.

Proliferative or preproliferative diabetic retinopathy is a contraindication per the tesamorelin label [11]. GH-driven IGF-1 elevation may worsen neovascularization. Screen all patients with long-standing diabetes with an ophthalmology exam before starting any GHS.

Pregnancy is a contraindication. MK-677 and peptide GHS agents have not been studied in pregnancy; fetal risk cannot be excluded. Tesamorelin is FDA Pregnancy Category X for its approved indication [11].

Drug Interactions

Glucocorticoids blunt GH response by increasing hypothalamic somatostatin tone; patients on chronic prednisone or dexamethasone may show attenuated GHS response. Insulin and oral hypoglycemics require dose monitoring when GHS-driven insulin resistance is suspected. No known CYP450-mediated drug interactions exist for peptide GHS, as they are cleared by peptidase-mediated proteolysis [5].

Monitoring Protocol

Systematic monitoring distinguishes safe GHS prescribing from unguided use. The following parameters should be tracked:

Baseline Evaluation

• IGF-1 (age- and sex-adjusted reference range). Target: maintain IGF-1 in the upper third of the normal range for age, not above the upper limit of normal (ULN) [16].
• Fasting glucose and HbA1c.
• Fasting lipid panel (VAT reduction with tesamorelin improves triglycerides; track this benefit) [4].
• Cancer screening up to date per USPSTF recommendations [19].
• Ophthalmology clearance in patients with diabetes lasting more than 5 years.

On-Treatment Monitoring

• IGF-1 at 4 to 6 weeks after starting, then every 3 months. If IGF-1 exceeds ULN, reduce dose by 50% or increase dosing interval before rechecking at 6 weeks.
• Fasting glucose at 3 months, then every 6 months.
• Subjective assessment of fluid retention (weight, ankle circumference) at each visit.
• HbA1c every 6 months in patients with prediabetes or existing type 2 diabetes.

Regulatory and Compounding Field

Tesamorelin (Egrifta SV, Theratechnologies) is the sole FDA-approved finished GHS drug product in the United States. All other GHS agents used in clinical practice, including ipamorelin, sermorelin, CJC-1295, and GHRP-2, are compounded preparations subject to 503A (patient-specific) or 503B (outsourcing facility) compounding regulations under the Drug Quality and Security Act of 2013.

In October 2023, the FDA placed ipamorelin on its Category 2 list of "difficult to compound" substances, signaling increased regulatory scrutiny of peptide compounding [20]. Prescribers must verify that their compounding pharmacy holds current 503A or 503B status and follows USP 797 sterility standards. The FDA has issued multiple warning letters to compounding pharmacies for peptide GHS products that failed sterility or potency testing.

MK-677 has never received FDA approval. It is an investigational compound, and its dispensing in the United States as a pharmaceutical product is not legally supported outside of an IND-approved protocol.

Patient Selection and Clinical Decision Framework

Candidates most likely to benefit from GHS therapy share several features: documented blunted GH response on stimulation testing (peak GH <7 ng/mL with GHRH or arginine), IGF-1 in the lower quartile for age, age over 35, and symptomatic concerns including reduced lean mass, increased visceral adiposity, or impaired recovery from exercise or injury.

GHS therapy is not appropriate for patients with IGF-1 already above the ULN, those with any active or recent malignancy within 12 months, patients with uncontrolled type 2 diabetes (HbA1c above 9.0%), or patients with proliferative retinopathy.

For adults on TRT seeking to preserve or restore GH axis function, ipamorelin 200 to 300 mcg SC nightly is a reasonable first-line GHS choice given its receptor selectivity and absence of cortisol or prolactin stimulation [9]. If visceral adiposity is the primary target and the patient qualifies (HIV-associated lipodystrophy), tesamorelin 2 mg SC daily is the only evidence-based, FDA-approved option [4].

Prescribers should document the clinical rationale for any off-label GHS use, obtain written informed consent that includes the non-FDA-approved status of compounded peptides, and establish a clear monitoring and discontinuation plan before the first prescription is written.